Diabetic Macular Edema
Rapid Response From Angiogenesis 2025: Advances in Treating Diabetic Macular Edema
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Connection emerging between obstructive sleep apnea, ocular conditions
Obstructive sleep apnea is a common breathing-related sleep disorder, with a growing prevalence due to the aging population and the rise of obesity.
Retinal Disease Digest on DME: Opportunities for Optometrists
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc., and Ocular Therapeutix, Inc.
Older patients with DME have weaker response to anti-VEGF treatment
Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at Angiogenesis, Exudation, and Degeneration 2025.
Dual inhibition with faricimab improves disease control in DME, neovascular AMD
Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema and neovascular age-related macular degeneration vs. aflibercept, according to study data.
Duravyu for DME meets primary, secondary endpoints in phase 2 trial
Duravyu at two dose levels met its primary endpoint in the treatment of diabetic macular edema in a phase 2 clinical trial, according to a press release from EyePoint Pharmaceuticals.
VIDEO: Positive data reported on OCS-05 in acute optic neuritis
KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the treatment of acute optic neuritis.
FDA approves Susvimo for diabetic macular edema
The FDA approved Susvimo for the treatment of diabetic macular edema, according to a press release.
VIDEO: OTX-TKI moves toward phase 3 trial for treatment of diabetic retinopathy
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for OTX-TKI, a tyrosine kinase inhibitor designed to block VEGFR-1, VEGFR-2 and VEGFR-3.
4D-150 for DME moving to phase 3 trial following positive interim data
4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.